CCR8 and neoplasm: To further test the utility of assessment of early TME responses to Treg cell depletion for identifying combinatory therapeutic modalities, we subjected KP tumor transplanted mice to a similar short-term treatment with CCR8 antibody and a selective CCR2 antagonist RS-504393 (CCR2i).